|
|
|
市場調査レポート
新興市場：サウジアラビアの医薬品市場
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
| 発行 |
Datamonitor |
| 出版日 |
2009年06月 |
商品コード |
90338 |
| ページ情報 |
英文 123 pages |
| 価格 |
|
|
Abstract
Introduction
The Saudi Arabian pharmaceutical sector is becoming increasingly attractive
for multinationals to enter driven by the expansion of private healthcare and
altering patient demographics; and also for domestic generics companies as the
government looks to evolve its cost saving strategies.
Scope of this research
- Overview of challenges faced by the Saudi Arabian healthcare system and a
review of the healthcare financing system reforms
- Analysis of trends observed in the pharmaceutical sector and the
development of the healthcare insurance sector
- Update of healthcare reforms undertaken in the Kingdom and thought-leader
insights into future changes to be implemented
- Commercial implications of the reforms for insurers, multinational and
domestic pharma companies, supported by Datamonitor strategic recommendations
Research and analysis highlights
Healthcare reforms in Saudi Arabia will increase access to healthcare services
and pharmaceuticals as the penetration of cooperative health insurance
increases across the Kingdom. Datamonitor forecasts this will result in a
significant increase in overall expenditure on drugs; however there will be a
greater shift towards generics use.
As competition increases, insurers will attempt to increase profits by
implementing cost containment measures such as pharmacoeconomic drug
evaluations, generic substitution and formulary lists. However, strong
underwriting policies, optimal pricing premiums, and delivering quality care
to members will remain critical.
Increasingly westernized lifestyles have driven up levels of chronic disease,
enhancing the need for drug intervention, with lifestyle products dominating
the retail market. Many branded drugs despite their off patent status still
command market leading sales and positive growth, underlining the preference
for branded drugs in the Saudi market.
Key reasons to purchase this research
- Understand the Saudi healthcare market and the strategic implications of
future reforms and how these will affect your business
- Identify opportunities for mutually beneficial relationships between your
firm and insurers which are becoming increasingly powerful stakeholders
- Gain insight into investment opportunities and create compelling cases for
strategic changes in your organization to adapt to the evolving market
Table of Contents
EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into P&R in Saudi Arabia
- Key opinion leaders interviewed
- Related reports
OVERVIEW OF THE HEALTHCARE CHALLENGES IN SAUDI ARABIA
- Key findings
- Future challenges facing healthcare in Saudi Arabia
- The growing demographics of Saudi Arabia
- Chronic illnesses are a major concern for authorities in Saudi Arabia
HEALTHCARE FINANCING IN SAUDI ARABIA
- Key findings
- Access to healthcare in Saudi Arabia is currently patchy
- Private healthcare expenditure is set to grow
- Healthcare in Saudi Arabia is primarily delivered through public channels
- Controlling costs in the public sector
- Change in distribution among private funding
- Healthcare reforms in Saudi Arabia aim to allow access to healthcare to
all individuals
- Healthcare reforms transfer the burden of financing private sector
employee healthcare from the Ministry of Health to employers
- Structural reforms seek to privatize hospitals
HEALTH INSURANCE IN SAUDI ARABIA
- Key findings
- Private versus public healthcare in Saudi Arabia
- The basic private health insurance coverage stipulated for Saudi Arabia is
the best in the region
- The Saudi insurance market will be a strategic growth area as nationals
are included
- The cooperative health insurance sector is a strategic growth area in
Saudi Arabia
- The Saudi healthcare insurance sector is well-regulated
- Key factors affecting growth in the burgeoning Saudi healthcare
insurance market
THE SAUDI ARABIAN PHARMACEUTICAL MARKET
- Key findings
- Pharmaceutical market dynamics in Saudi Arabia
- European drugs dominate the imports in Saudi Arabia
- Saudi generics manufacturers face a number of barriers to growth
- Generic drugs are widely used in the public sector, but not in the
private sector
- Pricing of generics and strong competition limits revenues
- Misleading information on generic medicine inserts impacts uptake
- Pharmacists play a significant and often unregulated role in dispensing
of brands over generics
- Patients are pressurizing physicians to prescribe generics
- Physicians in Saudi Arabia tend to overprescribe, use trade names and
are highly influenced by medical representatives
- Drug sales growth experienced across all therapy areas in Saudi Arabia
- An increasingly westernized lifestyle has increased the prevalence of
chronic diseases and the dependence on drugs
- Lifestyle products dominate the Saudi retail market
- Saudi Arabia is dominated by Big Pharma and regional generics manufacturers
- Domestic generics player are a key threat to international pharma
companies operating in Saudi Arabia
- Inorganic growth has been a successful growth strategy to date
- Saudi Arabia incentivizes local manufacturing
- Opportunities for clinical trials to generate region-specific
pharmacoeconomic data in the kingdom
- Companies should establish direct relationships with payers to ensure
formulary inclusion and maximum reimbursement
- Saudi Arabia offers generous endowments for research partnerships
HEALTHCARE REGULATORY AND GOVERNMENTAL ORGANIZATIONS
- Key findings
- The healthcare sector in Saudi Arabia consists of a complex network of
regulators
- Gulf Co-operative Council Health Ministers' Council has been a platform
for developing healthcare in the region
- Gulf Central Committee for Drug Registration
- Bulk purchasing of drugs has been a powerful cost-saving mechanism for
Gulf Cooperation Council governments
- The Ministry of Health is currently undergoing a transition towards a more
regulatory role
- Ministry of Health vaccination programs present opportunities for
vaccine manufacturers
- Combating diabetes will be one of the Ministry of Health' s key
regulatory roles
- Improving primary healthcare through family physicians
- The Saudi Food and Drug Authority' s role is to improve regulatory and
approval processes
- Drug approval is relatively straightforward in Saudi Arabia
- Concerns over intellectual property protection has placed Saudi Arabia
on the PhRMA Priority Watch List for 2009
- The Saudi national drug code is the first step in the development of a
unified healthcare management system in the kingdom
- The formation of the Council of Cooperative Health Insurance has
strengthened development of the insurance industry
- Future roles of the Council of Cooperative Health Insurance
PRICING AND REIMBURSEMENT IN SAUDI ARABIA
- Key findings
- Evolving pricing and reimbursement strategies in Saudi Arabia are required
to control healthcare expenditure
- The Ministry of Health controls drug prices in Saudi Arabia
- Price adjustments were enacted by the Ministry of Health in 2008
- New SFDA recommendations for drug pricing guidelines proposed
- Newly proposed changes to the common pricing criteria
- Pricing guidelines for innovative drugs before and after patent expiry
- Pricing guidelines for generic drugs
- Proposed changes to the pricing of locally manufactured second branded
drugs encourage contract manufacturing agreements
- Pricing guidelines for drugs with more than one active ingredient
- Saudi Food and Drug Authority recommends maximum price discounts on
drugs with larger packaging size or dose strength
- Additional new proposals submitted by the SFDA
- The use of pharmacoeconomic evaluations will change the face of Saudi drug
reimbursement
- Pharmacoeconomic evaluations are used globally
- Pharmacoeconomics is sporadically used in Saudi Arabia presently
- Saudi Arabia plans to integrate healthcare management centered around
pharmacoeconomics
BIBLIOGRAPHY
- Journals and online articles
TABLES
- Table: Saudi Arabia: health economics indicators, 2009
- Table: Saudi hospital statistics, 2005 - 06
- Table: Forecast of Saudi private sector hospital market revenues, 2006 -
2015
- Table: Comparison of Saudi Arabia' s basic insurance plan (CCHI) with Abu
Dhabi' s basic insurance plan (HAAD)
- Table: Top 10 pharmaceutical products in the retail market in Saudi
Arabia, 2008
- Table: Detailed procedures in applications for marketing authorization
from the Saudi Food and Drug Authority
- Table: Performance targets for Marketing Authorization Applications by the
Saudi Food and Drug Authority
- Table: Proposed price reductions for package sizes and doses
- Table: List of 30 reference countries used by Saudi Arabia to price drugs
- Table: Exchange rates, 2009
FIGURES
- Figure: Projected population growth in Saudi Arabia, 2000 - 2015
- Figure: Deaths in Saudi Arabia by cause, all age groups, 2002
- Figure: Distribution of health service provision by region in Saudi
Arabia, 2009
- Figure: Division of public and private expenditure on healthcare in Saudi
Arabia, 2006
- Figure: The Saudi health system in comparison with selected pharmaceutical
markets, 2009
- Figure: Healthcare service provision, by hospital beds, Saudi Arabia, 2005
- Figure: Shortcomings of the Ministry of Health in Saudi Arabia, 2009
- Figure: Private pre-paid plans and out-of-pocket expenditure as a
percentage of private expenditure on healthcare in Saudi Arabia, 2002 - 06
- Figure: Implementation of mandatory health insurance in Saudi Arabia, 2009
- Figure: Comparison of the effect of the cooperative health insurance
reforms on Saudi residents seeking treatment at public and private providers
- Figure: Number of insured individuals since the implementation of
cooperative health insurance in Saudi Arabia, Q3 2006 - Q2 2008
- Figure: Saudi health insurance market growth, 2005 - 07
- Figure: Proposed direct relationship between insurers and pharmaceuticals
in Saudi Arabia, 2009
- Figure: Growth of the Saudi Arabian pharmaceutical market, 2000 - 06
- Figure: Top 8 pharmaceutical exporting countries to Saudi Arabia, 2006
- Figure: Drug sales in the public and private pharmaceutical market in
Saudi Arabia, 2007
- Figure: Proportion of physicians who feel pressured by patients to
prescribe generic or branded drugs, 2008
- Figure: Physicians' source of information about generic alternatives
versus branded drugs
- Figure: Proportion of physicians who support generic drug substitution,
2008
- Figure: Saudi retail pharmacy sales by ATC class, 2007 - 08
- Figure: Retail sales and growth of top 10 pharmaceutical companies in
Saudi Arabia, 2007 - 08
- Figure: Leading domestic retail pharmaceutical manufacturers in Saudi
Arabia, 2008
- Figure: Relationship between regulators, payers, providers, users, and
suppliers, Saudi Arabia, 2009
- Figure: Six main components of Balsam project in Saudi Arabia
- Figure: Marketing Authorization process for generics, New Chemical
Entities, biologics and orphan drugs
- Figure: The 11-digit Saudi National Drug Code
- Figure: Future challenges and strategy of the Council of Cooperative
Health Insurance
- Figure: Global pricing and reimbursement strategies, 2009
- Figure: Profit margins for drugs in Saudi Arabia, 2004
- Figure: Comparison of retail drug prices in Saudi Arabia versus the United
Arab Emirates, 2009
- Figure: Revised common pricing criteria proposed by the Saudi Food and
Drug Authority, 2009
- Figure: Revised pricing guidelines for innovative drugs in Saudi Arabia
- Figure: Current and proposed new pricing guidelines for generic drugs in
Saudi Arabia
- Figure: Suggestions and rationale for the pricing of generics in Saudi
Arabia
- Figure: Suggestions and rationale for the pricing of drugs under license
in Saudi Arabia
- Figure: Pricing guidelines for drugs with more than one active ingredient
in Saudi Arabia
- Figure: Proposed healthcare management system in Saudi Arabia, 2009
|
 |
